Viridian Therapeutics, Inc.

Viridian Therapeutics, Inc.verified

VRDN

Price:

$15.74

Market Cap:

$1.00B

Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.[Read more]

Industry

Biotechnology

IPO Date

2014-06-18

Stock Exchange

NASDAQ

Ticker

VRDN

The PE Ratio as of July 2024 (TTM) for Viridian Therapeutics, Inc. (VRDN) is -3.36

According to Viridian Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -3.36. This represents a change of -23.90% compared to the average of -4.42 of the last 4 quarters.

Viridian Therapeutics, Inc. (VRDN) Historical PE Ratio (quarterly & annually)

How has VRDN PE Ratio performed in the past?

The mean historical PE Ratio of Viridian Therapeutics, Inc. over the last ten years is -4.89. The current -3.36 PE Ratio has changed 6.77% with respect to the historical average. Over the past ten years (40 quarters), VRDN's PE Ratio was at its highest in in the December 2020 quarter at -0.18. The PE Ratio was at its lowest in in the September 2014 quarter at -41.87.

Quarterly (TTM)
Annual

Average

-4.89

Median

-4.19

Minimum

-10.89

Maximum

-0.35

Viridian Therapeutics, Inc. (VRDN) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Viridian Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 462.77%

Maximum Annual PE Ratio = -0.35

Minimum Annual Increase = -93.89%

Minimum Annual PE Ratio = -10.89

Quarterly (TTM)
Annual
YearPE RatioChange
2023-4.10-45.12%
2022-7.47151.82%
2021-2.97462.77%
2020-0.5348.69%
2019-0.35-87.07%
2018-2.74-63.78%
2017-7.5776.99%
2016-4.28-46.63%
2015-8.01-26.43%
2014-10.89-93.89%

Viridian Therapeutics, Inc. (VRDN) Average PE Ratio

How has VRDN PE Ratio performed in the past?

The current PE Ratio of Viridian Therapeutics, Inc. (VRDN) is greater than its 3-year, less than than its 5-year, and greater than its 10-year historical averages

3-year avg

-4.85

5-year avg

-3.08

10-year avg

-4.89

Viridian Therapeutics, Inc. (VRDN) PE Ratio vs. Peers

How is VRDN’s PE Ratio compared to its peers?

Viridian Therapeutics, Inc.’s PE Ratio is greater than Nuvalent, Inc. (-35.52), greater than DICE Therapeutics, Inc. (-23.17), greater than Arcellx, Inc. (-64.53), greater than Vaxcyte, Inc. (-21.59), greater than Crinetics Pharmaceuticals, Inc. (-16.44), greater than Cytokinetics, Incorporated (-10.99), greater than Structure Therapeutics Inc. (-17.15), greater than Icosavax, Inc. (-8.27), greater than Pliant Therapeutics, Inc. (-4.47), greater than Syndax Pharmaceuticals, Inc. (-8.21), greater than Revolution Medicines, Inc. (-15.92), greater than Inozyme Pharma, Inc. (-4.58), greater than Terns Pharmaceuticals, Inc. (-7.05), greater than Blueprint Medicines Corporation (-24.73), greater than 89bio, Inc. (-5.31), greater than Kura Oncology, Inc. (-10.27), less than Protagonist Therapeutics, Inc. (15.73), greater than Merus N.V. (-21.45), less than Replimune Group, Inc. (-2.95), greater than Cerevel Therapeutics Holdings, Inc. (-17.12),

Build a custom stock screener for Viridian Therapeutics, Inc. (VRDN) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Viridian Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Viridian Therapeutics, Inc. (VRDN) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Viridian Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is Viridian Therapeutics, Inc.'s PE Ratio?

How is the PE Ratio calculated for Viridian Therapeutics, Inc. (VRDN)?

What is the highest PE Ratio for Viridian Therapeutics, Inc. (VRDN)?

What is the 3-year average PE Ratio for Viridian Therapeutics, Inc. (VRDN)?

What is the 5-year average PE Ratio for Viridian Therapeutics, Inc. (VRDN)?

How does the current PE Ratio for Viridian Therapeutics, Inc. (VRDN) compare to its historical average?